PFE.BA - Pfizer Inc.

Buenos Aires - Buenos Aires Delayed Price. Currency in ARS
842.35
0.00 (0.00%)
At close: 2:17PM ART
Stock chart is not supported by your current browser
Previous Close842.35
Open868.00
Bid0.00 x 0
Ask980.00 x 0
Day's Range842.35 - 868.00
52 Week Range307.20 - 900.00
Volume5,944
Avg. Volume352
Market Cap9.51T
Beta (3Y Monthly)0.95
PE Ratio (TTM)224.99
EPS (TTM)3.74
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2015-02-04
1y Target EstN/A
  • Reuters2 hours ago

    Merck, Pfizer combo treatment meets main goals of kidney cancer trial

    The combination resulted in statistically significant and clinically meaningful improvements in overall survival of the patients and helped patients survive without the cancer worsening, when compared to Pfizer's kidney cancer drug, Sutent. Keytruda is a blockbuster medicine that targets a blockade of proteins known as PD-1 and is approved for a range of other cancers, including lung cancer.

  • Reuters2 hours ago

    Merck, Pfizer combo treatment meets main goals of kidney cancer trial

    Merck & Co said on Thursday a combination treatment of its cancer drug Keytruda and Pfizer Inc's Inlyta met the main goals of a late-stage study in patients with the most common form of kidney cancer. The combination resulted in statistically significant and clinically meaningful improvements in overall survival of the patients and helped patients survive without the cancer worsening, when compared to Pfizer's kidney cancer drug, Sutent.

  • Is Sangamo Therapeutics Inc. a Buy?
    Motley Fool3 hours ago

    Is Sangamo Therapeutics Inc. a Buy?

    Can this beaten-down gene-editing and gene therapy biotech bounce back?

  • InvestorPlace16 hours ago

    Pfizer Layoffs: Company to Offer Early Retirement Deals Ahead of Cuts

    A new round of Pfizer layoffs (NYSE:PFE) has been announced by the pharmaceutical giant as the company is seeking to offer early retirement deals to some of its workers before gearing itself to carry out jobs cuts this year. The company made an internal announcement to its employees regarding the job cuts, although it is unclear how many of its 90,000 global workers it plans on laying off. “As we prepare for growth we are creating a simpler more efficient structure which will affect some managerial roles and responsibilities.

  • 2 Big Pharmas Pleased With J&J's Third-Quarter Earnings Report
    Motley Fool16 hours ago

    2 Big Pharmas Pleased With J&J's Third-Quarter Earnings Report

    Johnson & Johnson's latest earnings report suggests pricing concerns in the U.S. are overblown for pharmaceutical stocks with strong oncology exposure. Here's what you need to know.

  • Pfizer outlines early retirement program ahead of layoffs
    American City Business Journals20 hours ago

    Pfizer outlines early retirement program ahead of layoffs

    People who are 55 and have at least 10 years of service at the New York company may be eligible for early retirement.

  • Pfizer to cut around 2 percent of jobs through early next year
    Reuters20 hours ago

    Pfizer to cut around 2 percent of jobs through early next year

    U.S. drugmaker Pfizer Inc (PFE.N) plans to reduce its global headcount by around 2 percent through voluntary retirements and layoffs this year and early next year, as it looks to streamline its corporate structure and eliminate some managerial roles and responsibilities. Pfizer has around 90,000 employees worldwide. The move follows the announcement earlier this month that Chief Operating Officer Albert Bourla would succeed Ian Read as chief executive in January.

  • Reuters21 hours ago

    Pfizer to cut around 2 percent of jobs through early next year

    U.S. drugmaker Pfizer Inc plans to reduce its global headcount by around 2 percent through voluntary retirements and layoffs this year and early next year, as it looks to streamline its corporate structure and eliminate some managerial roles and responsibilities. Pfizer has around 90,000 employees worldwide. The move follows the announcement earlier this month that Chief Operating Officer Albert Bourla would succeed Ian Read as chief executive in January.

  • CNBC22 hours ago

    Drug giant Pfizer offers early retirement ahead of layoffs in memo to employees

    Pfizer is offering early retirement to eligible U.S. employees, ahead of layoffs next year. The pharmaceutical giant currently employs more than 90,000, according to data compiled by Factset. Pharmaceutical giant Pfizer PFE is offering early retirement to U.S. workers ahead of layoffs early next year, it announced internally to employees.

  • Top Research Reports for Pfizer, Caterpillar & Charter Communications
    Zacks23 hours ago

    Top Research Reports for Pfizer, Caterpillar & Charter Communications

    Top Research Reports for Pfizer, Caterpillar & Charter Communications

  • Pfizer (PFE) Gains But Lags Market: What You Should Know
    Zacks2 days ago

    Pfizer (PFE) Gains But Lags Market: What You Should Know

    In the latest trading session, Pfizer (PFE) closed at $43.92, marking a +1.86% move from the previous day.

  • What Nektar Therapeutics’ Valuation Trend Indicates
    Market Realist2 days ago

    What Nektar Therapeutics’ Valuation Trend Indicates

    In October, ten analysts are covering Nektar Therapeutics (NKTR) stock. Eight of them have given the stock a “buy” or higher rating, and two have given it a “hold.” The mean rating for the stock is 1.8 with a target price of $89.38, implying an upside potential of 82.1% over its closing price of $49.08 on October 15.

  • Analyzing Nektar Therapeutics’ Operational Performance
    Market Realist2 days ago

    Analyzing Nektar Therapeutics’ Operational Performance

    Nektar Therapeutics’ (NKTR) cost of goods sold was $5.52 million in the second quarter of 2018 compared to $8.99 million in the second quarter of 2017.

  • Reuters2 days ago

    FDA approves Pfizer's drug for advanced breast cancer

    The U.S. Food and Drug Administration said https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm623540.htm?utm_campaign=Oncology%2010%2F16%2F18%20talazoparib&utm_medium=email&utm_source=Eloqua&elqTrackId=3d45c5bae09748aa82b26d0d48f2c15b&elq=98e4248d80d04ab2907cce369a7c5176&elqaid=5513&elqat=1&elqCampaignId=4429 ...

  • Reuters2 days ago

    FDA approves Pfizer's breast cancer drug

    The U.S. Food and Drug Administration said https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm623540.htm?utm_campaign=Oncology%2010%2F16%2F18%20talazoparib&utm_medium=email&utm_source=Eloqua&elqTrackId=3d45c5bae09748aa82b26d0d48f2c15b&elq=98e4248d80d04ab2907cce369a7c5176&elqaid=5513&elqat=1&elqCampaignId=4429 ...

  • How Analysts View Merck Stock, Pre-Q3 Results
    Market Realist2 days ago

    How Analysts View Merck Stock, Pre-Q3 Results

    Between October 11 and 12, Merck (MRK) stock rose ~2.11% from $68.37 to close at $69.81. It was 32% higher than its 52-week low of $52.83 on April 3. Merck’s 52-week high is $72.89, reached on October 10.

  • US wants drug prices in TV ads: 'Patients deserve to know'
    Associated Press2 days ago

    US wants drug prices in TV ads: 'Patients deserve to know'

    TRENTON, N.J. (AP) — The federal government said Monday that it wants to force drugmakers to disclose prices for prescription medicines in their TV commercials.

  • Trump's Drug-Ad Price Shaming Won't Fix the Problem
    Bloomberg3 days ago

    Trump's Drug-Ad Price Shaming Won't Fix the Problem

    A series of tweets earlier this year managed to push pharmaceutical companies including Pfizer Inc. to temporarily halt price increases. Donald J. Trump @realDonaldTrump Pfizer & others should be ashamed that they have raised drug prices for no reason. The tactic is being taken to a new level with the administration’s plan, officially revealed Monday afternoon by Health and Human Services Secretary Alex Azar, to force drugmakers to disclose the list price of medicines available under Medicare or Medicaid in their TV ads. The main issue with the proposed rule is that a drug’s list or sticker price is very far from what many people or their health-care plans actually pay.

  • Merck’s Operating Expenditure and Recent Developments
    Market Realist3 days ago

    Merck’s Operating Expenditure and Recent Developments

    Merck’s (MRK) M&P (materials and production) expenses grew ~10% YoY (year-over-year) to $3.4 billion in the second quarter of 2018, while its M&A (marketing and administrative) expenses were flat YoY at $2.5 billion. The company’s R&D (research and development) expenses grew ~28% YoY to $2.3 billion from $1.8 billion, and its restricting expenditure grew 37% YoY to $228.0 million from $166.0 million. Analysts expect Merck to report non-GAAP M&P expenses of $2.7 billion in the third quarter, and non-GAAP R&D expenses of $2.0 billion.

  • What’s Expected for Merck’s Q3 2018 Earnings
    Market Realist3 days ago

    What’s Expected for Merck’s Q3 2018 Earnings

    Analysts expect Merck (MRK) to report GAAP net income of $2.23 billion and GAAP EPS of $0.83 in the third quarter of 2018. In Q2 2018, the company’s GAAP net income fell YoY (year-over-year) from $1.9 billion to $1.7 billion, and its GAAP EPS fell YoY from $0.71 to $0.63. Merck’s non-GAAP net income grew ~3% YoY in Q2 2018, to $2.9 billion from $2.8 billion, and its non-GAAP EPS grew ~5% YoY from $1.01 to $1.06.

  • Merck Is Expected to Record Steady Revenue Growth in Q3
    Market Realist3 days ago

    Merck Is Expected to Record Steady Revenue Growth in Q3

    Merck has announced it will be presenting its third-quarter revenue and earnings results on October 25. Analysts expect Merck to report revenue of $10.9 billion, primarily supported by Keytruda label expansions, Bridion, and its vaccine portfolio.

  • 3 Healthcare Stocks to Buy Amid the Carnage
    InvestorPlace3 days ago

    3 Healthcare Stocks to Buy Amid the Carnage

    My weekend scanning revealed relative strength emanating from healthcare stocks. For the brave souls who want to continue playing, I suggest looking for relative strength to buy. Here are three healthcare stocks to buy.

  • CNBC3 days ago

    Drugmakers will soon talk about price in ads — but not as explicitly as Trump administration wants

    Some drugmakers will soon tell consumers where they can see information about drug prices. Health and Human Services Secretary Alex Azar is expected on Monday to introduce a proposal that would require drugmakers to include the list price in their direct-to-consumer advertisements. This is a key piece of President Donald Trump's blueprint to lower drug prices.